Amino-terminally truncated mcp-2 as chemokine antagonists
CA 2305017 A1 · Owner: Van Damme, Jo · Inventors: Struyf, Sofie; Proost, Paul; Van Damme, Jo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to amino-terminally truncated MCP-2 lacking NH2-, terminal amino acids corresponding to amino acid residues 1 1-2, 1-3, 1-4 or , 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them their use in therapy and/or , in diagnosis of the diseases in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 28, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 28, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 28, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.